Alpha Tau Medical (NASDAQ:DRTS) Given “Buy” Rating at HC Wainwright

Alpha Tau Medical (NASDAQ:DRTS)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $16.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 22.23% from the stock’s previous close.

A number of other research firms have also recently weighed in on DRTS. Zacks Research cut shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Thursday. Barclays increased their target price on Alpha Tau Medical from $17.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, September 3rd. Finally, Benchmark restated a “buy” rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $15.40.

Alpha Tau Medical Trading Up 3.7%

NASDAQ DRTS traded up $0.47 during trading hours on Tuesday, hitting $13.09. 735,070 shares of the company’s stock were exchanged, compared to its average volume of 584,166. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -12.59 and a beta of 1.22. Alpha Tau Medical has a 1-year low of $3.43 and a 1-year high of $15.79. The stock has a 50-day simple moving average of $14.47 and a 200 day simple moving average of $11.73. The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Monday, August 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.36). On average, equities analysts forecast that Alpha Tau Medical will post -1.05 EPS for the current fiscal year.

Insider Transactions at Alpha Tau Medical

In other Alpha Tau Medical news, CFO Raphi Levy sold 17,730 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $14.00, for a total transaction of $248,220.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares in the company, valued at approximately $1,262,520. The trade was a 16.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 39.50% of the company’s stock.

Institutional Investors Weigh In On Alpha Tau Medical

Hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new stake in shares of Alpha Tau Medical in the 1st quarter valued at approximately $286,000. Principal Financial Group Inc. bought a new stake in shares of Alpha Tau Medical in the first quarter valued at about $132,000. Finally, Everhart Financial Group Inc. purchased a new stake in shares of Alpha Tau Medical in the 2nd quarter worth approximately $126,000. 2.65% of the stock is currently owned by hedge funds and other institutional investors.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is an Israel-based medical technology company focused on developing localized radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver high-energy alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses implanted radium-224 sources that generate short-lived alpha-emitting atoms. These atoms diffuse through the treated tumor and can damage cancer cells over a localized area.